24/7 MN – (NASDAQ: ANVS) wins FDA approval for late state Parkinson’s candidate. Shares are also up 22% $16.22 this morning on 5100 shares. And closing in on half a million shares in volume

[mstock id=”73007″ asset=”anvs”]

FDA Allows Annovis Bio To Proceed With Phase 3 Study Of Buntanetap In Parkinson’s Disease


NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.